SEARCH RESULTS FOR: "anab"
loading image
REFINE YOUR SEARCH:
ARTICLES/BLOGS
2021(1)
2020(1)
2019(2)
2018(2)
2017(1)
CATEGORIES
Buzz Stocks(3)
Investor Sentiment(1)
Midday Market Check(2)
Stock Market News(1)
Stocks On the Move(2)

3/8/2021 12:11 PM
extends its wild rally; and ANAB falls on trial results. One stock on the New York Stock, % in the last week. Conversely, the shares of AnaptysBio Inc (NASDAQ:ANAB) are down 36.1% at $18.83, . Gapping to its lowest levels since October of 2020, ANAB is now contending with its 320-day moving average
9/22/2020 7:39 AM
, Inc. (NASDAQ: ANAB -- $15.81) engages in developing therapeutic product candidates for inflammation
11/8/2019 2:39 PM
The U.S. stock market is drifting lower to end the week, as Wall Street waits in limbo for any U.S.-China trade developments. Two stocks stocks making vastly different moves today are skin disease specialists AnaptysBio Inc (NASDAQ:ANAB) and Dermira Inc (NASDAQ:DERM). Here's a quick look at what's moving the shares of ANAB and DERM. ANAB In Nasdaq Cellar After "Surprising" Eczema Drug Failure, , and called out AnaptysBio for a lack of investor call for such an important event. ANAB earlier hit a record
11/8/2019 11:55 AM
for the first time since early August. AnaptysBio Inc (NASDAQ:ANAB) is the worst stock on the Nasdaq, to postpone a Phase 11 study for its asthma drug. What's more, both Wedbush and Guggenheim downgraded ANAB
3/29/2018 10:29 AM
Brokerage firm Jefferies has been weighing in on a number of healthcare stocks this week, predicting big upside for AnaptysBio (ANAB) and Arrowhead Pharmaceuticals (ARWR). This morning, the firm turned its attention to Miragen Therapeutics Inc (NASDAQ:MGEN), initiating coverage with a "buy" rating and $14 price target -- well above the shares' Wednesday settlement at $6.82. The covering analyst suggested data from upcoming drug trials could push MGEN stock higher from its seemingly cheap
 
Special Offers from Schaeffer's Trading Partners